Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients

NACompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

April 3, 2020

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions
IMMUNOTHERAPY
Interventions
BIOLOGICAL

Convalescent plasma

400 ml of convalescent plasma (plasma taken 2 weeks from the recovered COVID-19 patients) and was transfused over 1-2 hours to the recipients by blood donation set.

DRUG

Hydroxychloroquin with Azithromycin

The control group of COVID-19 patients were given the conventional therapy approved in Iraq for COVID-19, namely Hydroxychloroquine 400mg PO twice per day for 5 days and Azithromycin once PO 500 mg per day for 5 days.

Trial Locations (1)

14222

Akarkh Healt hdirectorate, Baghdad

All Listed Sponsors
lead

Alkarkh Health Directorate-Baghdad

OTHER_GOV

NCT04441424 - Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients | Biotech Hunter | Biotech Hunter